Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months. Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit immune surveillance in CLL. This phase 2 study was de...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Ding, Wei, LaPlant, Betsy R., Call, Timothy G., Parikh, Sameer A., Leis, Jose F., He, Rong, Shanafelt, Tait D., Sinha, Sutapa, Le-Rademacher, Jennifer, Feldman, Andrew L., Habermann, Thomas M., Witzig, Thomas E., Wiseman, Gregory A., Lin, Yi, Asmus, Erik, Nowakowski, Grzegorz S., Conte, Michael J., Bowen, Deborah A., Aitken, Casey N., Van Dyke, Daniel L., Greipp, Patricia T., Liu, Xin, Wu, Xiaosheng, Zhang, Henan, Secreto, Charla R., Tian, Shulan, Braggio, Esteban, Wellik, Linda E., Micallef, Ivana, Viswanatha, David S., Yan, Huihuang, Chanan-Khan, Asher A., Kay, Neil E., Dong, Haidong, Ansell, Stephen M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2017
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5492091/
https://ncbi.nlm.nih.gov/pubmed/28424162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-765685
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller